688428 诺诚健华
交易中 04-16 09:30:41
资讯
新帖
简况
诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%
证券之星 · 04-15 22:05
诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%
诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户
证券日报 · 04-07
诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户
每周股票复盘：诺诚健华（688428）证券数量无变动
证券之星 · 04-05
每周股票复盘：诺诚健华（688428）证券数量无变动
诺诚健华（688428）披露证券变动月报表，4月3日股价下跌1.9%
证券之星 · 04-03
诺诚健华（688428）披露证券变动月报表，4月3日股价下跌1.9%
3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股
证券之星 · 03-30
3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股
高盛：微升诺诚健华(09969)目标价至19.93港元 上季奥布替尼销售稳健
智通财经 · 03-30
高盛：微升诺诚健华(09969)目标价至19.93港元 上季奥布替尼销售稳健
诺诚健华（688428）2025年年报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 03-27
诺诚健华（688428）2025年年报简析：营收净利润同比双双增长，盈利能力上升
诺诚健华（688428）披露2025年年度报告，3月26日股价下跌0.08%
证券之星 · 03-26
诺诚健华（688428）披露2025年年度报告，3月26日股价下跌0.08%
瑞银：降诺诚健华(09969)目标价至19.8港元 维持“买入”评级
智通财经 · 03-26
瑞银：降诺诚健华(09969)目标价至19.8港元 维持“买入”评级
诺诚健华(09969)：练少娥获委任为公司秘书、授权代表
智通财经 · 03-25
诺诚健华(09969)：练少娥获委任为公司秘书、授权代表
诺诚健华(09969)公布2025年业绩 税后利润约6.44亿元 同比扭亏为盈
智通财经 · 03-25
诺诚健华(09969)公布2025年业绩 税后利润约6.44亿元 同比扭亏为盈
每周股票复盘：诺诚健华（688428）将召开2025年年度业绩说明会
证券之星 · 03-22
每周股票复盘：诺诚健华（688428）将召开2025年年度业绩说明会
诺诚健华（688428）披露召开2025年年度业绩说明会公告，3月17日股价上涨1.27%
证券之星 · 03-17
诺诚健华（688428）披露召开2025年年度业绩说明会公告，3月17日股价上涨1.27%
港股异动 | 诺诚健华(09969)早盘涨超5% 自研VAV1分子胶降解剂ICP-538完成首例受试者给药
智通财经网 · 03-17
港股异动 | 诺诚健华(09969)早盘涨超5% 自研VAV1分子胶降解剂ICP-538完成首例受试者给药
诺诚健华宣布中国首款获批临床的VAV1分子胶降解剂ICP-538完成首例受试者给药
证券日报 · 03-16
诺诚健华宣布中国首款获批临床的VAV1分子胶降解剂ICP-538完成首例受试者给药
诺诚健华宣布国内首例健康受试者完成新型Vav1降解剂ICP-538临床试验给药
美股速递 · 03-16
诺诚健华宣布国内首例健康受试者完成新型Vav1降解剂ICP-538临床试验给药
诺诚健华（688428）披露董事会将于近日召开以审议2025年全年业绩，3月12日股价下跌1.15%
证券之星 · 03-12
诺诚健华（688428）披露董事会将于近日召开以审议2025年全年业绩，3月12日股价下跌1.15%
诺诚健华：公司预计2025年度首次实现扭亏为盈
证券日报 · 03-11
诺诚健华：公司预计2025年度首次实现扭亏为盈
3月10日诺诚健华涨6.01%，富国精准医疗混合A基金重仓该股
证券之星 · 03-10
3月10日诺诚健华涨6.01%，富国精准医疗混合A基金重仓该股
每周股票复盘：诺诚健华（688428）股本结构稳定无新增发行
证券之星 · 03-08
每周股票复盘：诺诚健华（688428）股本结构稳定无新增发行
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":30.4,"timestamp":1776303041000,"preClose":31.17,"halted":0,"volume":552640,"delay":0,"changeRate":-0.0247,"floatShares":268000000,"shares":1764999999,"eps":0.9779,"marketStatus":"交易中","change":-0.77,"latestTime":"04-16 09:30:41","open":30.86,"high":30.86,"low":30.38,"amount":16924200,"amplitude":0.0154,"askPrice":30.4,"askSize":0,"bidPrice":30.38,"bidSize":31,"shortable":0,"etf":0,"ttmEps":0.9779,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1776310200000},"marketStatusCode":2,"adr":0,"adjPreClose":31.17,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776303000000,1776310200000],[1776315600000,1776322800000]],"highLimit":34.29,"lowLimit":28.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":7.12,"roa":"--","peRate":31.087023,"roe":"9.02%","epsLYR":0.38,"committee":-0.515093,"marketValue":53645000000,"turnoverRate":0.0021,"status":1,"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":15.25,"timestamp":1776303034783,"preClose":15.56,"halted":0,"volume":163000,"delay":0,"premium":"-56.35"},"floatMarketCap":8158000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2627238931","title":"诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238931","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627238931?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:05","pubTimestamp":1776261917,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，诺诚健华报收于31.17元，较前一交易日上涨7.93%，最新总市值为550.04亿元。该股当日开盘29.49元，最高31.82元，最低28.88元，成交额达6.28亿元，换手率为7.74%。公告显示，公司将于2026年4月24日上午11:00-12:00通过上证路演中心网络互动方式召开2026年第一季度业绩说明会，介绍公司当季经营成果及财务状况。投资者可于4月17日至4月23日16:00前通过上证路演中心网站或公司邮箱IR@innocarepharma.com提交问题。说明会后可通过该平台查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500042904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625934106","title":"诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2625934106","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625934106?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:14","pubTimestamp":1775556840,"startTime":"0","endTime":"0","summary":"证券日报网讯4月7日，诺诚健华在互动平台回答投资者提问时表示，截至2026年3月20日公司A股股东户数约为1.93万户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696569528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","688428","BK0239","399300","BK1161","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625151786","title":"每周股票复盘：诺诚健华（688428）证券数量无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2625151786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625151786?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:17","pubTimestamp":1775323029,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，诺诚健华报收于29.38元，较上周的25.3元上涨16.13%。本周，诺诚健华4月2日盘中最高价报30.29元。诺诚健华当前最新总市值518.45亿元，在化学制药板块市值排名9/150，在两市A股市值排名357/5193。本周关注点公司公告汇总：诺诚健华截至2026年3月31日证券数量无变动，股份总数与上月底结存一致。此外，2023年及2024年人民币股股权激励计划项下部分限制性股票失效，但本月未因协议安排导致股份增减。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","161027","09969","688428","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624366824","title":"诺诚健华（688428）披露证券变动月报表，4月3日股价下跌1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624366824","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624366824?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:05","pubTimestamp":1775225120,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，诺诚健华报收于29.38元，较前一交易日下跌1.9%，最新总市值为518.45亿元。该股当日开盘29.51元，最高30.16元，最低28.6元，成交额达6.59亿元，换手率为8.32%。近日，诺诚健华发布港股公告《证券变动月报表》。公告显示，截至2026年3月31日，公司法定注册资本无变动，已发行股份总数与上月底结存一致，无增减。此外，2023年及2024年人民币股股权激励计划项下部分限制性股票失效，但本月未因协议安排导致股份增减。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","161027","BK1574","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623281397","title":"3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623281397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623281397?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:26","pubTimestamp":1774859203,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日诺诚健华涨7.08%创60日新高，收盘报27.09元，换手率9.07%，成交量24.33万手，成交额6.52亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值3.126，较上一交易日上涨6.93%，近一年上涨22.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623947623","title":"高盛：微升诺诚健华(09969)目标价至19.93港元 上季奥布替尼销售稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623947623","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623947623?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:23","pubTimestamp":1774855423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，诺诚健华去年第四季奥布替尼销售额为3.9亿元人民币，同比增长27%，2025年销售额同比升41%，符合公司之前的指引。该行维持对诺诚健华H股的“买入”评级，将目标价由19.91港元微升至19.93港元。该行基于诺诚健华的最新业绩，将2026至28财年的净利润预测分别下调2,900万元、6,300万元及7,000万元人民币，以反映研发开支因扩展技术平台而有所上升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622222894","title":"诺诚健华（688428）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622222894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622222894?lang=zh_cn&edition=full","pubTime":"2026-03-27 06:07","pubTimestamp":1774562825,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诺诚健华发布2025年年报。截至本报告期末，公司营业总收入23.75亿元，同比上升135.27%，归母净利润6.42亿元，同比上升245.81%。本报告期诺诚健华盈利能力上升，毛利率同比增幅6.57%，净利率同比增幅160.46%。经营活动产生的现金流量净额变动幅度为122.95%,原因:药品销售收入增加及收到授权许可款项。公司奥布替尼2025年第四季度药品销售收入保持环","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700008396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622585826","title":"诺诚健华（688428）披露2025年年度报告，3月26日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622585826","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622585826?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:16","pubTimestamp":1774516613,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，诺诚健华报收于24.29元，较前一交易日下跌0.08%，最新总市值为428.63亿元。该股当日开盘25.0元，最高25.5元，最低24.15元，成交额达4.49亿元，换手率为6.8%。公司于近日披露《诺诚健华医药有限公司2025年年度报告》。公告显示，公司2025年实现营业收入23.75亿元，同比增长135.27%；归属于上市公司股东的净利润为6.42亿元，同比扭亏为盈；经营活动产生的现金流量净额为8390.14万元。公司2025年度不进行利润分配，母公司存在未弥补亏损-30.31亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622832779","title":"瑞银：降诺诚健华(09969)目标价至19.8港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622832779","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622832779?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:59","pubTimestamp":1774511979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，基于去年下半年业绩，下调诺诚健华2026及2027年销售预测，并上调开支预测，导致2026及27年每股盈利预测由0.06元及0.22元，下调至0.04元及0.20元。目标价由21.1港元下调至19.8港元，维持“买入”评级。诺诚健华去年下半年收入及纯利分别为16亿元人民币(下同)及6.73亿元，大致符合初步业绩。研发开支同比增长16.9%至9.52亿元，占产品销售比例由81%降至66%。该行称，诺诚健华今年指引略逊预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622205220","title":"诺诚健华(09969)：练少娥获委任为公司秘书、授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2622205220","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622205220?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:08","pubTimestamp":1774436925,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，李谢佩珊女士已提请辞任公司的公司秘书，并就香港联合交易所有限公司证券上市规则第3.05条而言，不再担任公司的授权代表;及根据公司条例(香港法例第622章)第16部规定，不再担任公司于香港接收送达法律程序文件及通知的法定代表(法律程序代理人)，自2026年3月25日起生效。此外，练少娥女士已获委任为公司秘书、授权代表及法律程序代理人，自2026年3月25日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09969","BK1161","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622302709","title":"诺诚健华(09969)公布2025年业绩 税后利润约6.44亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2622302709","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622302709?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:00","pubTimestamp":1774436401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布2025年业绩，收益约23.75亿元，同比增长135.27%;税后利润约6.44亿元，同比扭亏为盈;经调整利润约6.75亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售的强劲增长，以及与Zenas Biopharma及Prolium合作所产生的许可收益。药物收益同比增加43.4%至14.424亿元，是由于奥布替尼持续的高增长，以及坦昔妥单抗于2025年第四季度上市。公司首次实现扭亏为盈，达成重要里程碑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","688428","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621799324","title":"每周股票复盘：诺诚健华（688428）将召开2025年年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2621799324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621799324?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:38","pubTimestamp":1774118291,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，诺诚健华报收于23.69元，较上周的23.26元上涨1.85%。本周，诺诚健华3月20日盘中最高价报24.75元。本周关注点公司公告汇总：诺诚健华将于2026年3月26日召开2025年年度业绩说明会。公司公告汇总诺诚健华医药有限公司将于2026年3月26日上午11:00-12:00通过上海证券交易所上证路演中心以网络互动方式召开2025年年度业绩说明会，介绍公司年度经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","09969","BK1161","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620734334","title":"诺诚健华（688428）披露召开2025年年度业绩说明会公告，3月17日股价上涨1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620734334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620734334?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:19","pubTimestamp":1773757158,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，诺诚健华报收于23.84元，较前一交易日上涨1.27%，最新总市值为420.69亿元。该股当日开盘23.55元，最高24.52元，最低23.31元，成交额达2.33亿元，换手率为3.62%。近日，诺诚健华医药有限公司发布关于召开2025年年度业绩说明会的公告。公告显示，公司将于2026年3月26日上午11:00-12:00通过上海证券交易所上证路演中心以网络互动方式召开2025年年度业绩说明会，介绍公司年度经营成果及财务状况。说明会后可通过该平台查看会议情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700041967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688428","09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620414204","title":"港股异动 | 诺诚健华(09969)早盘涨超5% 自研VAV1分子胶降解剂ICP-538完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620414204","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620414204?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:08","pubTimestamp":1773716898,"startTime":"0","endTime":"0","summary":"诺诚健华(09969)早盘涨超5%，截至发稿，涨3.41%，报12.42港元，成交额5455.45万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260317/20260317110839_40999.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260317/20260317110839_40999.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK0239","09969","VXUS","BK1574","688428","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619458991","title":"诺诚健华宣布中国首款获批临床的VAV1分子胶降解剂ICP-538完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458991","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619458991?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:07","pubTimestamp":1773648443,"startTime":"0","endTime":"0","summary":"3月16日，诺诚健华医药有限公司（以下简称“诺诚健华”）宣布，中国首款、全球第二款进入临床的VAV1分子胶降解剂ICP-538完成首例受试者给药。ICP-538是诺诚健华自主研发的新型口服高效、高选择性靶向VAV1的特异性分子胶降解剂，VAV1是T细胞和B细胞受体下游的关键蛋白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673100474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","BK1161","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159897748","title":"诺诚健华宣布国内首例健康受试者完成新型Vav1降解剂ICP-538临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1159897748","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159897748?lang=zh_cn&edition=full","pubTime":"2026-03-16 09:41","pubTimestamp":1773625278,"startTime":"0","endTime":"0","summary":"诺诚健华近日宣布，其自主研发的新型Vav1降解剂ICP-538在国内临床试验中完成对首例健康志愿者的首次给药。这一里程碑标志着该创新药物正式进入临床开发阶段，为后续研究奠定重要基础。\nICP-538作为靶向Vav1蛋白的小分子降解剂，通过特异性诱导目标蛋白降解发挥治疗作用。此次临床试验旨在评估该药物在人体内的安全性、耐受性及药代动力学特征，为拓展其适应症范围提供关键数据支持。\n随着首例受试者顺利完成给药，研究团队将按计划推进后续剂量递增及安全性观察工作。该进展不仅体现了诺诚健华在创新药物研发领域的加速布局，也展现出中国生物医药企业在新靶点探索方面的技术实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618129130","title":"诺诚健华（688428）披露董事会将于近日召开以审议2025年全年业绩，3月12日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618129130","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618129130?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:37","pubTimestamp":1773326232,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，诺诚健华报收于23.13元，较前一交易日下跌1.15%，最新总市值为408.16亿元。该股当日开盘23.4元，最高23.58元，最低22.93元，成交额达1.42亿元，换手率为2.28%。诺诚健华于近日披露公告，公司董事会宣布将于2026年3月25日举行会议，考虑及批准本公司及其附属公司截至2025年12月31日止之全年业绩及其发布。董事会成员包括崔霁松博士、赵仁滨博士、施一公博士、谢榕刚先生、胡兰女士、董丹丹博士及管坤良教授。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200038998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1574","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618928493","title":"诺诚健华：公司预计2025年度首次实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928493","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618928493?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:36","pubTimestamp":1773236199,"startTime":"0","endTime":"0","summary":"证券日报网讯3月11日，诺诚健华在互动平台回答投资者提问时表示，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。公司对于未来包括奥布替尼在内的药品销售、管线进展及商业化合作充满信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113669094746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","09969","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618619980","title":"3月10日诺诚健华涨6.01%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618619980","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618619980?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:22","pubTimestamp":1773130927,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日诺诚健华涨6.01%，收盘报23.81元，换手率3.62%，成交量9.71万手，成交额2.29亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值2.8444，较上一交易日下跌1.51%，近一年上涨16.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1574","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663338","title":"每周股票复盘：诺诚健华（688428）股本结构稳定无新增发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663338?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:00","pubTimestamp":1772910037,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，诺诚健华报收于22.68元，较上周的23.3元下跌2.66%。本周，诺诚健华3月2日盘中最高价报23.48元。诺诚健华当前最新总市值400.22亿元，在化学制药板块市值排名11/150，在两市A股市值排名521/5190。本周关注点公司公告汇总：诺诚健华截至2026年2月28日股本无变动，已发行股份总数为1,496,284,235股。另有于上交所科创板上市的人民币股份268,359,717股。公司确认公众持股量符合港交所上市规则要求。存在股权激励计划安排，但本月未发生新股发行或库存股转让。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776303044443,"stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.3241},{"period":"3month","weight":0.4162},{"period":"6month","weight":0.3124},{"period":"1year","weight":0.7336},{"period":"ytd","weight":0.519}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20000人(较上一季度增加3.63%)","perCapita":"13417股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}